Tyche Peer Comparison

BSE: 532384

₹107.60

₹-2.15 (-1.96%)

As on 24-Sep-2026 09:40IST

Market cap

₹112 Cr

Revenue (TTM)

₹50 Cr

P/E Ratio

25.2

P/B Ratio

0.8

Div. Yield

3.2 %

Edit

	Tyche	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Market cap (₹ Cr)	112	37,585	28,859	16,982	16,312
Revenue (₹ Cr)	50	9,683	2,372	2,590	1,108
Net Profit (₹ Cr)	4.46	1,018.97	497.77	603.02	270.18
Net Margin (%)	7.46	10.47	20.72	22.63	23.29
RoE (%)	3.17	21.30	28.49	19.61	14.45
Price to Earnings	25.25	37.16	57.98	28.16	59.23
Price-To-Book	0.80	7.19	14.28	4.87	7.87

Income Statement (₹ Cr)

	Tyche	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Operating Revenue	50.03	9,683.45	2,371.81	2,590.40	1,108.39
Total Income	59.75	9,730.84	2,402.61	2,664.23	1,159.90
Total Expenditure	51.44	7,739.53	1,608.91	1,753.71	720.01
EBITDA	-1.40	1,943.92	762.90	836.69	388.38
Depreciation	2.17	425.10	98.11	78.88	74.78
EBIT	-3.57	1,518.82	664.79	757.81	313.60
Interest	0.00	148.45	26.33	5.43	0.26
Other Income	9.72	47.39	30.80	73.83	51.50
Exceptional Items	0.00	-27.85	0.00	-25.66	-3.28
Profit before Tax	6.15	1,389.91	669.26	800.55	361.56
Provision for Tax	1.69	370.94	171.48	197.53	91.39
Profit after Tax	4.46	1,018.97	497.77	603.02	270.18

	Tyche	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Shareholder's Funds	140.47	4,950.03	1,874.47	3,332.13	2,017.06
Minority Interest	0.00	-7.58	0.00	0.00	2.51
Non-Current Liabilities	1.02	723.57	345.47	142.73	50.51
Current Liabilities	6.56	3,912.24	710.20	508.04	169.08
Total Liabilities	151.26	8,121.73	2,179.88	3,753.59	2,034.25

	Tyche	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Non-Current Assets	18.88	3,392.16	1,290.62	1,321.38	957.22
Current Assets	107.95	5,612.10	1,483.13	2,649.36	1,250.11
Total Assets	151.26	8,121.73	2,179.88	3,753.59	2,034.25
Total Debt*	0.00	731.70	136.01	0.00	0.38
Net Current Assets	101.39	1,699.86	772.93	2,141.33	1,081.04
Contingent Liabilities	0.35	393.94	8.97	4.82	3.91

	Tyche	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Cash From Operating Activities	8.54	851.71	317.40	391.52	244.52
Cash Flow from Investing Activities	-0.62	-94.00	-298.16	-615.65	-159.99
Cash from Financing Activities	-2.56	-813.96	24.96	-6.23	-98.77
Net Cash Inflow / Outflow	5.37	-56.25	44.21	-230.35	-14.24

	Tyche	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
ROCE (%)	12.69	22.49	23.45	25.50	29.62
ROE (%)	3.17	21.30	28.49	19.61	14.45
ROA (%)	3.02	11.42	19.48	16.31	12.66
EBIT Margin (%)	-7.13	15.68	28.03	29.25	28.29
Net Margin (%)	7.46	10.47	20.72	22.63	23.29
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Tyche	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Revenue Growth (%)	-21.02	18.36	78.33	7.93	-6.72
EBIT Growth (%)	-138.06	30.43	303.07	19.88	-26.64
Net Profit Growth (%)	-63.21	32.39	182.61	21.66	-24.38
EPS Growth (%)	-64.72	36.68	277.72	25.42	-21.99
Book Value Growth (%)	7.86	50.94	18.89	20.94	18.74

	Tyche	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Price / Earnings	25.23	36.40	57.98	27.27	58.72
Price / Book Value	0.80	7.19	14.28	4.87	7.87
Dividend Yield (%)	3.19	0.18	0.15	0.36	0.48
EV/EBITDA	-20.12	19.88	37.62	19.36	40.93
Market Cap (₹ Cr)	136.31	20,327.45	15,494.53	13,228.83	17,537.35

	Tyche	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debt to Equity	0.00	0.05	0.09	0.00	0.00
Short term debt to equity ratio	--	0.11	--	--	0.00
Current Ratio	16.46	1.43	2.09	5.21	7.39
Quick Ratio	14.95	0.82	1.37	3.85	5.46
Interest Coverage	0.00	10.36	26.41	148.49	1,386.30

	Tyche	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debtors to sales (%)	39.06	26.46	22.82	41.42	41.52
Asset Turnover	0.34	1.09	0.93	0.70	0.52
Receivable days	101.01	87.83	85.17	132.12	132.49
Inventory Days	81.39	78.64	90.97	102.08	68.07
Payable days	70.62	174.97	137.94	133.54	123.94
Cash Conversion Cycle	111.78	-8.50	38.21	100.66	76.63

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.